Recipharm Invests in Sythonics

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-05-06-2015
Volume 11
Issue 5

Recipharm makes a strategic investment in Synthonics and partners in development of novel compounds.

 

Recipharm announced on April 14, 2015 that it made an equity investment in Synthonics Inc., a specialty pharmaceutical company focused on the discovery, development and licensing of metal-coordinated pharmaceuticals, and purchased $2.0 million of preferred stock in the company.

A further $2.0 million of preferred stock will be purchased upon Synthonics’ achievement of certain milestones, which could be expected during 2016. 

In addition, Synthonics and Recipharm have entered into a joint development agreement under which Synthonics gains access to Recipharm’s expertise in drug development, marketing, and manufacturing in exchange for a royalty payment on certain of Synthonics’ compounds.

Synthonics has developed a drug delivery technology for metal coordination of pharmaceutical APIs. In connection with its investment, Recipharm’s Carl-Johan Spak has joined Synthonics’ board of directors. 

Source: Recipharm

 

Recent Videos
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Leroy Hood, MD, PhD
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Related Content